Suppr超能文献

A20是一种抗原呈递衰减因子,对其抑制作用可克服调节性T细胞介导的抑制作用。

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.

作者信息

Song Xiao-Tong, Evel-Kabler Kevin, Shen Lei, Rollins Lisa, Huang Xue F, Chen Si-Yi

机构信息

Center for Cell and Gene Therapy, Baylor College of Medicine (BCM), One Baylor Plaza, Houston, Texas 77030, USA.

出版信息

Nat Med. 2008 Mar;14(3):258-65. doi: 10.1038/nm1721. Epub 2008 Mar 2.

Abstract

Regulatory T cells (T(reg) cells) suppress autoreactive immune responses and limit the efficacy of tumor vaccines; however, it remains a challenge to selectively eliminate or inhibit T(reg) cells. In this study, the zinc-finger A20, a negative regulator of the Toll-like receptor and tumor necrosis factor receptor signaling pathways, was found to play a crucial part in controlling the maturation, cytokine production and immunostimulatory potency of dendritic cells (DCs). A20-silenced DCs showed spontaneous and enhanced expression of costimulatory molecules and proinflammatory cytokines and had different effects on T cell subsets: they inhibited T(reg) cells and hyperactivated tumor-infiltrating cytotoxic T lymphocytes and T helper cells that produced interleukin-6 and tumor necrosis factor-alpha and were refractory to T(reg) cell-mediated suppression. Hence, this study identifies A20 as an antigen presentation attenuator in control of antitumor immune responses during both the priming and the effector phases and provides a strategy to overcome T(reg) cell-mediated suppression in an antigen-specific manner, reducing the need to directly target T(reg) cells.

摘要

调节性T细胞(Treg细胞)可抑制自身反应性免疫应答并限制肿瘤疫苗的疗效;然而,选择性消除或抑制Treg细胞仍然是一项挑战。在本研究中,发现锌指蛋白A20作为Toll样受体和肿瘤坏死因子受体信号通路的负调节因子,在控制树突状细胞(DC)的成熟、细胞因子产生和免疫刺激能力方面发挥着关键作用。A20沉默的DC显示出共刺激分子和促炎细胞因子的自发且增强的表达,并且对T细胞亚群有不同影响:它们抑制Treg细胞并使肿瘤浸润性细胞毒性T淋巴细胞和产生白细胞介素-6和肿瘤坏死因子-α且对Treg细胞介导的抑制具有抗性的辅助性T细胞过度活化。因此,本研究确定A20是在启动期和效应期控制抗肿瘤免疫应答过程中的抗原呈递减弱因子,并提供了一种以抗原特异性方式克服Treg细胞介导的抑制的策略,减少了直接靶向Treg细胞的必要性。

相似文献

2
In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response.
PLoS One. 2015 Sep 1;10(9):e0135444. doi: 10.1371/journal.pone.0135444. eCollection 2015.
3
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells.
J Clin Invest. 2011 Feb;121(2):739-51. doi: 10.1172/JCI42656. Epub 2011 Jan 4.
7
The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity.
Immunity. 2011 Jul 22;35(1):82-96. doi: 10.1016/j.immuni.2011.05.013. Epub 2011 Jun 30.
8

引用本文的文献

1
Dissecting the dual role of OTU family proteins in tumor progression and immune escape.
Front Immunol. 2025 May 21;16:1544341. doi: 10.3389/fimmu.2025.1544341. eCollection 2025.
2
Advances and prospects of RNA delivery nanoplatforms for cancer therapy.
Acta Pharm Sin B. 2025 Jan;15(1):52-96. doi: 10.1016/j.apsb.2024.09.009. Epub 2024 Sep 14.
3
Role of Ubiquitin Signaling in Modulating Dendritic Cell Function.
Adv Exp Med Biol. 2024;1466:101-111. doi: 10.1007/978-981-97-7288-9_7.
4
Hepatitis B surface antigen impairs TLR4 signaling by upregulating A20 expression in monocytes.
Microbiol Spectr. 2024 Oct 3;12(10):e0090924. doi: 10.1128/spectrum.00909-24. Epub 2024 Sep 9.
6
Investigation of the Molecular Evolution of Treg Suppression Mechanisms Indicates a Convergent Origin.
Curr Issues Mol Biol. 2023 Jan 9;45(1):628-648. doi: 10.3390/cimb45010042.
8
Application of lipid-based nanoparticles in cancer immunotherapy.
Front Immunol. 2022 Aug 8;13:967505. doi: 10.3389/fimmu.2022.967505. eCollection 2022.
9
Cold-catalytic antitumor immunity with pyroelectric black phosphorus nanosheets.
Chem Sci. 2022 May 17;13(23):6842-6851. doi: 10.1039/d2sc01894b. eCollection 2022 Jun 15.

本文引用的文献

2
OX40 costimulation turns off Foxp3+ Tregs.
Blood. 2007 Oct 1;110(7):2501-10. doi: 10.1182/blood-2007-01-070748. Epub 2007 Jun 15.
3
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.
Nat Med. 2007 Apr;13(4):423-31. doi: 10.1038/nm1564. Epub 2007 Mar 25.
4
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
5
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
J Clin Invest. 2006 Jul;116(7):1935-45. doi: 10.1172/JCI27745. Epub 2006 Jun 15.
7
Dendritic cell-based tumor vaccines and antigen presentation attenuators.
Mol Ther. 2006 May;13(5):850-8. doi: 10.1016/j.ymthe.2006.02.009. Epub 2006 Mar 30.
8
Regulatory T cells, tumour immunity and immunotherapy.
Nat Rev Immunol. 2006 Apr;6(4):295-307. doi: 10.1038/nri1806.
9
Human T cell responses against melanoma.
Annu Rev Immunol. 2006;24:175-208. doi: 10.1146/annurev.immunol.24.021605.090733.
10
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells.
Blood. 2006 Jul 1;108(1):253-61. doi: 10.1182/blood-2005-11-4567. Epub 2006 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验